iPSC-Derived Platelet Compositions for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing platelets are inefficient, leading to shortages and limited effectiveness of platelet transfusions, and existing drug delivery methods, particularly for protein-based therapeutics, fail to leverage physiological processes for targeted delivery.
Innovation Solution
The production of induced pluripotent stem cell (iPSC)-derived megakaryocytic progenitors, megakaryocytes, proplatelets, and platelets, which can be loaded with therapeutic agents through receptor-mediated, passive, or covalent conjugation, and used for targeted drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If nanoparticle-based approaches are used for drug delivery, then tissue-targeted delivery of small molecules is improved, but protein-based therapeutics cannot be packaged due to their larger size
Solution Approach 1:
The patent uses platelets as intermediary carriers that can accommodate both small molecules and protein-based therapeutics. Platelets naturally circulate in the bloodstream and can be engineered to carry diverse therapeutic agents, bridging the gap between nanoparticle delivery efficiency and protein therapeutic compatibility.
Solution Approach 2:
The patent changes the carrier size parameter from nanoparticle scale to platelet scale (1-3 μm), which is large enough to accommodate protein-based therapeutics yet small enough to leverage physiological processes for targeted delivery to injury sites.
2Quantity of substance
If donor platelets are used for transfusion, then platelet supply is maintained, but wide functional variability limits transfusion effectiveness
Solution Approach 1:
The patent uses iPSCs to self-produce platelets in vitro, eliminating dependence on donor variability. The standardized culture conditions and differentiation protocols ensure consistent platelet function and quality, allowing on-demand production of reliable platelet units.
Solution Approach 2:
The patent creates copies of functional platelets from iPSCs that can be differentiated into megakaryocytes and then platelets with controlled and consistent properties, replacing the variable donor-derived platelets with standardized laboratory-produced units.
3Quantity of substance
If more platelet units are produced from donors, then platelet shortages are addressed, but production efficiency remains limited
Solution Approach 1:
The patent performs preliminary expansion of megakaryocytic progenitors in vitro before generating platelets, allowing a small number of iPSCs to produce large numbers of platelet units. This preliminary expansion step dramatically increases production efficiency and overcomes donor limitations.
Solution Approach 2:
The patent employs dynamic culture conditions including agitation and controlled oxygen tension to optimize megakaryocyte maturation and platelet release, enhancing productivity throughout the differentiation process.
Data Source
AI summary
Methods for producing megakaryocytes and platelets derived from inducible pluripotent stem cells and comprising a therapeutic agent are provided. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.